EXAGEN INC.: NMSIC Co-Investment Fund, L.P. amends Schedule 13G stake filing
Not investment advice. Muhabbit scores how much a story may matter, not which way to trade.
NMSIC Co-Investment Fund, L.P. filed an amended Schedule 13G with the SEC (accession 0001140361-26-043757) updating its beneficial ownership stake in Exagen Inc. The filing, made under the short-form 13G regime used by passive and institutional holders, revises the fund's previously reported position in the diagnostics company. The amendment signals a change in NMSIC's holdings, though the filing notice did not disclose the revised share count or percentage. Investors will watch for the full filing details to gauge whether the shift reflects passive rebalancing or a broader change in institutional sentiment toward Exagen.
Muhabbit's AI wrote this summary in its own words from SEC EDGAR SCHEDULE 13G's report. It can get details wrong, so check the source.
Named in this story
NMSIC Co-Investment Fund, L.P., EXAGEN INC.